The elevated levels of interleukin-13 (IL-13) and the protein periostin seen in the whole blood samples taken from patients who had uncontrolled prurigo nodularis (PN) compared with a group of ...

Dupilumab, a fully human monoclonal antibody that blocks interleukin-4 and interleukin-13, has shown efficacy in patients with asthma and elevated eosinophil levels. The blockade by dupilumab of ...

Ebglyss is a targeted interleukin-13 inhibitor approved for the treatment of moderate-to-severe atopic dermatitis. It can be used with or without topical corticosteroids. Eli Lilly and Company ...

Significantly greater reductions in the mean esophageal eosinophil counts occurred in patients who received the humanized anti-interleukin 13 antibody, RPC4046. SEATTLE — RPC4046, a humanized ...

SAN DIEGO, March 13, 2013 /PRNewswire/ – Receptos Inc. announced today that it has entered a Development License and Option Agreement to in-license a humanized anti-interleukin-13 (IL-13 ...

Dupilumab is a human monoclonal antibody that blocks interleukin-4 and interleukin-13 pathways and has shown efficacy in five different atopic diseases marked by type 2 inflammation, including ...

Researchers discovered an unexpected link between zinc deficiency, the pro-inflammatory cytokine interleukin-13 (IL-13), and Acinetobacter baumannii lung infection and demonstrated that blocking ...

Dupixent is a human monoclonal antibody specifically designed to inhibit signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two important signaling proteins (cytokines) that contribute ...

SAN DIEGO, March 13, 2013 /PRNewswire/ -- Receptos Inc. announced today that it has entered a Development License and Option Agreement to in-license a humanized anti-interleukin-13 (IL-13 ...